Scrip Watch

Krebs Biochemicals & Industries Ltd

Scrip Sanctuaries for protection from the wildlife in this jungle of Indian Equities

Krebs Biochemicals & Industries Ltd

Krebs Biochemicals & Industries Ltd
Pharmaceuticals
FV – Rs 10; 52wks H/L –165/76.90; TTQ – 2 K; CMP – Rs 103 (As On May 5th 2016; 11:00) ;

Market Cap – Rs 127.87 Crs

Standalone Financials and Valuations for 9Months FY16 (Amt in Rs.Crs unless specified)


Equity Capital

Net worth
Long Term Debt
Total
Sales
PAT
BV
(Rs)

TTM EPS (Rs)

TTM P/E

Industry P/E

P/BV

Promoter’s
Stake
Beta
12.41 -14 65 0.9 -10.31 -11 – 8.31 33.53 57.67

 

Standalone Financials and Valuations for FY15 (Amt in Rs Crs unless specified)


Equity Capital

Net worth
Long Term Debt
Total
Sales
PAT
BV
(Rs)

EPS (Rs)

P/E

P/BV
Beta
9.51 -5 57 0.01 -7.84 -22 -8.24

 

IPCA Labs picked up 23 Lacs shares (26%) in Krebs Biochemicals ltd through an open offer at Rs.54/- per share.

(http://www.thehindubusinessline.com/markets/ipca-labs-to-pick-up-26-stake-in-krebs-bio/article6891198.ece)

The successful completion of USFDA (United States of Food and Drug administration) audit and its approval for Unit-I is an added advantage for the Company to attract good customers.

The company didn’t record turnover during the period on account of closure of both the manufacturing plants due to power shortage in Andhra Pradesh.

Reserves of the company decreased from Rs.6 Crs to Rs.14 Crs due to increased losses during the year.

Overview:

  • Krebs Biochemicals and Industries Ltd is an India-based company engaged in the business of manufacture of active pharmaceutical ingredients.
  • The Company is producing a number of pain killers, anti-asthmatic and anti-human immunodeficiency virus (HIV) drugs under contract manufacturing.
  • The Company offers Simvastatin and Lovastatin as anti-cholesterols, and Ephedrine and Pseudo ephedrine as anti-asthmatic.
  • The Company’s products under development include Adenine as an intermediate for Tenofovir Anti HIV; Atorvastatin Intermediates as Anti Cholesterols; Phenylephrine for Cough and cold, and Orlistat against obesity.

The Company has two manufacturing facilities one at Regadichelaka, Nellore and another one at Kothapalli Village, Kasimkota Mandal, Vishakapatnam, both in India.

The company has entered in to an agreement with M/s Edelweiss Asset Reconstruction Co. Ltd. for repayment of the assigned debt by Exim Bank in instalments commencing from June, 2015.

 

Industry Updates:

  • Global Pharmaceutical Industry is estimated now to be US $ 1 trillion and is growing at a rate of 4-5% per annum. Pharmaceutical industry is facing many challenges and uncertainties.
  • A number of Big Generics based Pharmaceutical companies have emerged in India over the past decade and are driving the growth in the Pharmaceutical sector in India.
  • India’s own requirement of pharmaceuticals is seeing a steady and significantly higher than world average growth. This is the very reason large Pharma companies are eyeing the Indian market and trying to grab a slice of the pie by way of acquisitions and large marketing outlays.

Management:

  • Dr. R. T. Ravi – Chairman
  • Mr. Avinash Ravi – MD

Major Non-Promoter Holdings:

Sr.No Non – Promoters No. of Shares held % of shares held
1 K. Satish 245869 1.98
2 Edelweiss Asset Reconstruction Co.Ltd 150000 1.21
3 Shaaji palliyath 150000 1.21
4 Pinky Ventures Private Ltd 600000 4.83
5 Sun Pharmaceutical Industries Ltd 1050000 8.46
  Total 2195869 17.69

 

 

Standalone Financial Trends (In Rs.Crs):

Particulars FY15 FY14 FY13 FY12 FY11
Equity Paid Up 9.51 9.51 9.51 9.51 9.05
Networth -5 4 8 23 39
Total Debt 57 25 76 80 85
Net Sales 0.01 0.2 18 74 79
Other Income 0.01 0.2 6 3 7
PAT -7.84 -4.35 -15.2 -17.44 -6.68
Book Value (Rs) -5 4 8 24 43
EPS (Rs) -8.24 -4.57 -15.98 -18.34 -7.38

 

The numbers are of 6 months ended FY15 and 15 months for FY14 (Sept 14) and same for FY13.

Only FY11 and FY12 are 12 months ended.

The Company announced to consider and allot 650000 equity shares and 680000 warrants convertible to Equity shares of Rs.10 each on preferential basis.

 

 

 

 

 

 

 

 

 

 

 

 

 

Excerpts from Gaurav’s Blog

  Rest in Peace now Gerela Saab  ! Mr S T Gerela ex GM of BSE passed away peacefully this morning We had not met in years but he always remained at the top of my mind when it came to testimonials for this is what he had said to me over a decade ago,when […] [...]

Vedanta de-listing offer price Rs 87.50~Come on Mr Anil Agarwal ! Promoter Group of  Vedanta Ltd has proposed a voluntary de-listing at an indicative offer price of Rs 87.50~are the over 7.3 lakh minority shareholders from Alibag !? …apologies to the people of Alibag Some would term this as De-listing Duplicity ~ but I would […] [...]

This is a Riskless Reliance Industries Rights Investment Strategy for those over 2.3 Million Shareholders already holding RIL shares. It is not a recommendation to buy RIL cum rights  It’s a no brainer yet I’m just penning a brief note because some have told me they hold Reliance but are skipping the Rights ! Don’t […] [...]

 Wealth is negotiable, Health is not Your Personal Well Being is more important that the Stock Market Well Being ~ Always & more so in this unfathomable ongoing Covid-19 Reality Above’s a three minute reach out by me last night to all connected with me to reinforce this .It’s also posted on Facebook , […] [...]

Yes Bank ~ Has the RBI & MOF lost it !? SEBI really is a bystander here Controversial Lock In Clause 3 Sub Clause 8 (a) in the Scheme of Reconstruction  No wonder the Finance Minister Mrs Nirmala Sitharaman, while highlighting only selected points, even when asked for details of the Scheme,did not want to […] [...]